/R E P E A T -- Pathways to improving Indigenous Peoples' health: Focusing on sex and gender to improve Indigenous health/
WHITEHORSE, Sept. 25, 2017 /CNW/ - Mark your calendars! This September 25-27, you are invited to Whitehorse, Yukon to take part in the third Pathways Annual Gathering co-led by CIHR and the Native Women's Association of Canada. Event participants will discuss finding new ways to improve the health of Indigenous peoples by integrating sex and gender into research.
If you can't attend, CIHR's Scientific Director Dr. Carrie Bourassa is available to discuss the event, research on Indigenous peoples' health, and the need to deliver culturally safe care.
At the Canadian Institutes of Health Research (CIHR), we know that research has the power to change lives. As Canada's health research investment agency, we collaborate with partners and researchers to support the discoveries and innovations that improve our health and strengthen our health care system. www.cihr-irsc.gc.ca
Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended...
EditCo Bio, Inc., a pioneer at the forefront of genome engineering innovation, today announced the launch of its Knockout CD4+ T-cell Pools. This latest addition to EditCo Bio's product lineup marks a significant leap forward in CRISPR-mediated gene...
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open.
Management...
Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, today announced the U.S. Food & Drug Administration (FDA) approved the company's New...
Vertex Pharmaceuticals Incorporated today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an...
Visibly, developer of the world's first FDA-cleared online visual acuity test, has appointed John Ryan as a Strategic Advisor focused on their continued growth into the managed care and insurance space. With this appointment, Ryan brings his...
